Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Medical Technology
  • Page 42
fda’s-device-chief-calls-for-more-authority-to-address-supply-chain-shortages-impacting-pediatric,-neonatal-patients
Posted inMedical Technology

FDA’s device chief calls for more authority to address supply chain shortages impacting pediatric, neonatal patients

January 17, 2025
While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are…
Read More
wuxi-apptec-sells-us-medical-device-testing-business-to-namsa
Posted inMedical Technology

WuXi AppTec sells US medical device testing business to NAMSA

January 17, 2025
WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based…
Read More
jpm25:-ge-healthcare,-ucsf-launch-research-hub-for-cancer,-neurodegenerative-disease-imaging
Posted inMedical Technology

JPM25: GE HealthCare, UCSF launch research hub for cancer, neurodegenerative disease imaging

January 15, 2025
SAN FRANCISCO—GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at improving…
Read More
fda-elevates-philips-cardiac-telemetry-recall-over-unflagged-ecg-alerts,-following-2-deaths
Posted inMedical Technology

FDA elevates Philips cardiac telemetry recall over unflagged ECG alerts, following 2 deaths

January 15, 2025
The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help…
Read More
jpm25:-dexcom-predicts-2025-growth,-with-stelo-pushing-portfolio-updates
Posted inMedical Technology

JPM25: Dexcom predicts 2025 growth, with Stelo pushing portfolio updates

January 14, 2025
SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have…
Read More
jpm25:-medtronic-begins-rolling-out-adaptive-brain-stimulation-for-parkinson’s-after-eu-approval
Posted inMedical Technology

JPM25: Medtronic begins rolling out adaptive brain stimulation for Parkinson’s after EU approval

January 13, 2025
SAN FRANCISCO—While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a…
Read More
jpm25:-regeneron,-illumina-and-more-back-truveta-for-10m-genome-sequencing-project
Posted inMedical Technology

JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project

January 13, 2025
Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts…
Read More
jpm25:-guardant-health-posts-31%-sales-gain-as-cancer-blood-tests-expand
Posted inMedical Technology

JPM25: Guardant Health posts 31% sales gain as cancer blood tests expand

January 13, 2025
SAN FRANCISCO—In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million…
Read More
saluda-medical-toasts-$100m-fundraising-to-pep-up-sales-of-its-closed-loop-neurostimulator
Posted inMedical Technology

Saluda Medical toasts $100M fundraising to pep up sales of its closed-loop neurostimulator

January 10, 2025
The neuromodulation developer Saluda Medical announced that it raised $100 million to help bolster the sales of its closed-loop implant aimed…
Read More
insilico-medicine-licenses-2nd-ai-generated-cancer-drug-candidate-to-menarini’s-stemline-in-$550m-deal
Posted inMedical Technology

Insilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M deal

January 9, 2025
Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group. Following a licensing agreement last…
Read More

Posts pagination

Previous page 1 … 40 41 42 43 44 … 46 Next page

Privacy Policy    Terms

Scroll to Top